| SAW PalmettoResearch score 14/100 · Mixed/Weak | 3 systematic reviews/meta-analyses + 1 randomised trial — 4 studies | 3/17 outcomes showed benefit- Functional Assessment of Cancer Therapy-Prostate prostate-specific concerns scoreReported a benefit — see exact figuresbenefit2016 study ↗
Exact figures(P = 0.03) n=21 · Follow-up: 22 weeks · Sample (as reported): 21 · Recorded unit: Not reported · Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. · Randomized Controlled Trial · rct · PMID 26891611 - International Prostate Symptom Score (IPSS) — a urinary symptom questionnaireNo clear difference (0.63 higher, unit not reported)no benefit2020 study ↗
Exact figures0.63 (95% CI [-0.33, 1.59], p = 0.20) n=1,080 · Follow-up: at least 6-month treatment cycle · Sample (as reported): 1,080 · Recorded unit: Not reported · Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. · Meta-Analysis · meta-analysis · PMID 32274957 - Prostate-specific antigen (PSA) — a prostate blood markerNo clear difference (0.46 higher, unit not reported)no benefit2020 study ↗
Exact figures0.46 (95% CI [-0.06, 0.97], p = 0.08) n=1,080 · Follow-up: at least 6-month treatment cycle · Sample (as reported): 1,080 · Recorded unit: Not reported · Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. · Meta-Analysis · meta-analysis · PMID 32274957 - Prostate sizeNo clear difference (1.22 cc lower)no benefit2012 study ↗
Exact figures-1.22 (95% CI -3.91 to 1.47) · Follow-up: Not reported · Sample (as reported): Not reported · Recorded unit: cc · Serenoa repens for benign prostatic hyperplasia. · Meta-Analysis · meta-analysis · PMID 23235581 +13 more outcomes → |
|---|